Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (pSS) open-label proof of concept ASAP study).

sjogrens syndrome

  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,610 posts
  • Location:West Sussex

Posted 12 June 2014 - 11:32 AM

Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (pSS) open-label proof of concept ASAP study).

 

Abatacept is effective, safe and well tolerated. It results in improved disease activity, laboratory parameters, fatigue and health-related quality of life in patients with early and active pSS. PubMed, Ann Rheum Dis, 2014 Jan 28. (Also see: Sjogren's Syndrome)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)